Table 3.

Details of Fatal Cases

Patient No.	Sex/Age (Year)	Formulation	Dose Ingested (Grams)	Timea to Hospital (Hours)	Initial Severity	Clinical Manifestations	Timeb to Death
1	Male/47	Unknown	NA	2	Severe	Coma and cardiopulmonary arrest	2 days
2	Male/52	70% WG	20	NA	Severe	Nausea/vomiting, diaphoresis, hypotension, tachycardia, progressive coma, cardiovascular collapse.	5 hours after arrival
3	Female/64	10% w/v SL	NA	8	Moderate	Dizziness, dyspnea, tachycardia and hypertension, respiratory failure and cardiac arrest	13 hours
4	Male/88	35% w/v EC	70	1	Mild	Tachypnea, diaphoresis, mental status changes, hypotension, tachycardia, and prolonged shock	22 hours
5	Female/49	10% w/v SL	40	6	Mild	Nausea/vomiting, burning sensation of throat, dyspnea, confusion, and cardiopulmonary arrest	2 days

Notes: ^aDuration from exposure to arrival at healthcare facility. ^b Time until patient died after ingestion.

Abbreviations: NA, not applicable; WG, water-dispersible granules; w/v, weight by volume; SL, soluble concentrates; EC, emulsifiable concentrates.